A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Eli Lilly and Company
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Pheon Therapeutics
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
BeOne Medicines
Boehringer Ingelheim
Zymeworks BC Inc.
Nammi Therapeutics Inc
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
IDEAYA Biosciences
Pfizer
Revolution Medicines, Inc.
Conjupro Biotherapeutics, Inc.
DeuterOncology
Alterome Therapeutics, Inc.
Pfizer
Whitehawk Therapeutics, Inc.
SystImmune Inc.
Pfizer
Conjupro Biotherapeutics, Inc.
RasCal Therapeutics, Inc.
Pfizer
Xencor, Inc.
Amgen
ViroMissile, Inc.
Replimune, Inc.
Abdera Therapeutics Inc.
Pfizer
Tizona Therapeutics, Inc
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Clasp Therapeutics, Inc.
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Revolution Medicines, Inc.
SystImmune Inc.
Pheon Therapeutics
Xemed LLC
Eli Lilly and Company
Seagen Inc.
Phrontline Biopharma
AgonOx, Inc.
Novartis
Sichuan Baili Pharmaceutical Co., Ltd.
Nuvectis Pharma, Inc.
Dizal Pharmaceuticals
TILT Biotherapeutics Ltd.
Seagen Inc.
Shanghai Juncell Therapeutics
Degron Therapeutics Co.